|Dr. Alexey L. Margolin||Co-Founder & Chairman||427.95k||N/A||1953|
|Dr. Louis Brenner||Pres, CEO & Director||507.28k||N/A||1970|
|Mr. Edward J. Wholihan||Chief Financial Officer||387.03k||N/A||1960|
|Mr. Robert Gallotto||Co-Founder & Strategic Adviser||N/A||N/A||1965|
|Mr. Hugh Wight||Sr. VP of Technical Operations||N/A||N/A||N/A|
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was founded in 2011 and is headquartered in Newton, Massachusetts.
Allena Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.